Each tablet contains 2.5 mg indapamide hemihydrate.
Each tablet contains 103.1 mg of spray dried lactose
The dosage is one tablet, containing 2.5 mg indapamide hemihydrate, daily, to be taken in the morning.
The action of indapamide is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy. A larger dose than 2.5 mg indapamide daily is not recommended as there is no appreciable additional antihypertensive effect but a diuretic effect may become apparent. If a single daily tablet of indapamide does not achieve a sufficient reduction in blood pressure, another antihypertensive agent may be added; those which have been used in combination with indapamide include beta-blockers, ACE inhibitors, methyldopa, clonidine and other adrenergic blocking agents. The co-administration of indapamide with diuretics which may cause hypokalaemia is not recommended.
There is no evidence of rebound hypertension on withdrawal of indapamide.
Patients with renal impairment
In severe renal failure (creatinine clearance below 30 ml/min), treatment is contraindicated.
Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired.
Patients with hepatic impairment
In severe hepatic impairment, treatment is contraindicated.
As for adults.
In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with indapamide when renal function is normal or only minimally impaired.
Indapamide is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.
Method of administration
Indapamide tablets are for oral administration only.
- Hypersensitivity to indapamide, to other sulfonamides or to any of the excipients
- Severe renal failure.
- Hepatic encephalopathy or severe impairment of liver function.